Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Vaccine|July 20, 2017
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trialAnuradha Madan, Harry Collins, Eric Sheldon, et al.
NPJ Vaccines|December 19, 2017
A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in miceRaffael Nachbagauer, David Kinzler, Angela Choi, et al.
The Journal of Infectious Diseases|November 14, 2009
Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trialJiri Beran, Timo Vesikari, Veronika Wertzova, et al.
Human Vaccines|February 3, 2011
Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adultsJames D Campbell, Christopher V Chambers, Rebecca C Brady, et al.
Vaccine|February 4, 2014
Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trialJuan Carlos Tinoco, Noris Pavia-Ruz, Aurelio Cruz-Valdez, et al.
The Journal of Infectious Diseases|May 17, 2006
Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccinationWellington Sun, Ananda Nisalak, Montip Gettayacamin, et al.
Vaccine|October 9, 2017
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trialOpokua Ofori-Anyinam, Geert Leroux-Roels, Mamadou Drame, et al.
Journal of Clinical Microbiology|February 8, 2003
Rapid detection of adenovirus in throat swab specimens by PCR during respiratory disease outbreaks among military recruitsMarcela Echavarria, Jose L Sanchez, Shellie A Kolavic-Gray, et al.
Journal of the Pediatric Infectious Diseases Society|November 15, 2019
Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort StudySuchitra Rao, Emad Yanni, Angela Moss, et al.
Vaccine|February 12, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trialAnuradha Madan, Murdo Ferguson, Eric Sheldon, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Vaccine|July 20, 2017
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trialAnuradha Madan, Harry Collins, Eric Sheldon, et al.
NPJ Vaccines|December 19, 2017
A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in miceRaffael Nachbagauer, David Kinzler, Angela Choi, et al.
The Journal of Infectious Diseases|November 14, 2009
Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trialJiri Beran, Timo Vesikari, Veronika Wertzova, et al.
Human Vaccines|February 3, 2011
Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adultsJames D Campbell, Christopher V Chambers, Rebecca C Brady, et al.
Vaccine|February 4, 2014
Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trialJuan Carlos Tinoco, Noris Pavia-Ruz, Aurelio Cruz-Valdez, et al.
The Journal of Infectious Diseases|May 17, 2006
Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccinationWellington Sun, Ananda Nisalak, Montip Gettayacamin, et al.
Vaccine|October 9, 2017
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trialOpokua Ofori-Anyinam, Geert Leroux-Roels, Mamadou Drame, et al.
Journal of Clinical Microbiology|February 8, 2003
Rapid detection of adenovirus in throat swab specimens by PCR during respiratory disease outbreaks among military recruitsMarcela Echavarria, Jose L Sanchez, Shellie A Kolavic-Gray, et al.
Journal of the Pediatric Infectious Diseases Society|November 15, 2019
Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort StudySuchitra Rao, Emad Yanni, Angela Moss, et al.
Vaccine|February 12, 2017
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trialAnuradha Madan, Murdo Ferguson, Eric Sheldon, et al.
Pageof 12